An Economic Evaluation of Colesevelam when Added to Metformin-, Insulin- or Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus

Abstract

In adult patients with T2DM, the addition of colesevelam to metformin-, insulin- or sulfonylurea-based therapies significantly improves glycaemic control while also reducing LDL-C, and these improvements could translate into substantial cost reductions due to reductions in the rates of diabetes-related and cardiovascular complications.

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)

“…The predictive performance of UKPDS‐OM2 when using these risk factor equations was significantly improved relative to an assumption of holding risk factors constant and more accurately reflects the deterioration in metabolic control observed in the UKPDS cohort. More recent therapies or interventions may enable participants to improve the control of risk factors, and many recent economic evaluations involve comparisons of new therapies with the glucose‐lowering medications that were included in the UKPDS 23–26 …”

“…More recent therapies or interventions may enable participants to improve the control of risk factors, and many recent economic evaluations involve comparisons of new therapies with the glucose-lowering medications that were included in the UKPDS. [23][24][25][26] Our analysis has a number of limitations. First, the data used to estimate the equations are increasingly historical and may in some cases reflect values or trajectories that are less commonly seen in contemporary populations.…”

Clinical Efficacy of Colesevelam in Type 2 Diabetes Mellitus

“…Simons and Hagan recently conducted a pharmacoeconomic analysis on the cost-effectiveness of the addition of colesevelam to metformin, sulfonylurea, or insulin. 80 The analysis evaluated data from 3 randomized controlled trials in which the addition of colesevelam to established metformin, sulfonylurea, or insulin therapy conferred an additional HbA1c reduction of approximately 0.5% ( P < .001) compared to baseline. 33,53,54 Validated models (diabetic risk equation [DRE] and the LIPID cardiovascular risk equation [LCRE]) were used to translate the observed clinical effects of colesevelam to monetary savings.…”